CDK4/6 Inhibitors in the First-line Treatment Setting

CDK 4/6 Inhibitors in Breast Cancer Advanced and Adjuvant SettingsПодробнее

Real-world progression-free survival data on delaying CDK4/6 inhibitorsПодробнее

Sequencing first-line CDK4/6 inhibitors in metastatic breast cancerПодробнее

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...Подробнее

Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BCПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

2023 Updates In Metastatic Breast Cancer TreatmentПодробнее

FDA Approved AKT Inhibitor for Patients With Advanced HR-Positive Breast CancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

Education Session: Treatment Post CDK 4/6 InhibitorsПодробнее

Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: Real-World Data and EvidenceПодробнее

Optimizing CDK4/6 Inhibition in HR+ Breast CancerПодробнее

Advanced Breast Cancer: Challenges in Pathways DevelopmentПодробнее

Report Back From ASCO on Metastatic Breast CancerПодробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

When to Choose Chemotherapy vs CDK4/6 InhibitorsПодробнее

CDK4/6 Plus Endocrine Therapy as First-Line ApproachПодробнее

CDK4/6 Inhibitors & Endocrine Therapy in Breast CancerПодробнее

Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast CancerПодробнее

CDK 4/6 Inhibitor as First-Line Therapy for Advanced Breast CancerПодробнее